Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: Cacaito who wrote (3973)	12/21/1997 2:01:00 PM
From: LoLoLoLita	Read Replies (1) \| Respond to of 23519

>>100 mg dose study just published in the Journal of Urology >>in November or December issue, from Brazil with no FDA to >>protect patients from high dose (this is probably the >>highest dose used for Yohimbine in a formal study) Cacaito-- 100 mg? My Lord!, those people should called "victims" not "patients"!!! How many ended up in the ER/ICU with hypotensive shock? Don't the pharmacists have an old saw that "the only difference between a drug and a poison is in the dose"? David

To: Cacaito who wrote (3973)	12/21/1997 9:38:00 PM
From: BigKNY3	Read Replies (1) \| Respond to of 23519

Cacaito <<BigKNY3, I do share your frustration with the constant tirade of PFE did this or that against Vivus. Pfizer has never attack Vivus in any form but competing with their science>> Cacaito: I appreciated your comments. PFE probably has very little interest in going after MUSE. Frankly, sales of $200 million would be a major disappointment. Blaming PFE for VVUS' woes or attacking Viagra is just an indication of investor frustration with VVUS. Over the long-term, I believe VVUSers may very well benefit from the introduction of Viagra. BigKNY3